JPRN-UMIN000005433已完成4 期
A multicenter,openlabel,randomized controlled traial for the head-to-head comparison of minodronic acid hydroate and raloxifene hydrocloride - A-TOP/JOINT-04
Research committee of A-TOP0 个研究点目标入组 3,500 人开始时间: 2011年4月13日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Using therapeutic drug contraindications,Secondary osteoporousis and Disease with low bone mass, Advanced variant T4-L4, Heart disease,liver disease,kidney failure or other serious complications Problems with the reliability of interview data Treatment of malignant tumors that may affect bone metabolism
研究者
相似试验
进行中（未招募）
不适用
A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/?L in HIV-infected patients with CD4 counts remaining between 101-350 cells/?L after at least 2 years of HAART and plasma HIV RNA < 50 copies/mL for 18 months. - INSPIRE 3HIV infected patientsMedDRA version: 9.1Level: PTClassification code 10020161EUCTR2010-019773-15-ITCYTHERIS80
已完成
不适用
An open-label, multicenter, randomized, controlled, parallel-group comparative study on the effectiveness of carbohydrate-counting and calorie-counting as a dietary management in type 2 diabetic patients treated without insulin therapyType 2 diabetes mellitusJPRN-UMIN0000015884C-study Research Group200
尚未招募
3 期
A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine (LDT600) 600 mg PO in combination with peg alpha-2a sq 180 µg with peg alpha-2a monotherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive CHB.hepatitis Bliver inflammation10047438NL-OMON30611ovartis10
进行中（未招募）
不适用
A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine LDT600 600 mg PO in combination with peg alpha-2a sq 180 g with peg alpha-2a monotherapy, and with telbivudine monotherapy in treatment na ve patients with HBeAg-positive compensated CHB - NDCHB Chronic Hepatitis BMedDRA version: 8.1Level: LLTClassification code 10019736Term: Hepatitis B antibody positiveEUCTR2006-004003-18-ITOVARTIS FARMA300
进行中（未招募）
1 期
A randomized, open-label, controlled, multi-center Phase II study to evaluate the efficacy and safety of adecatumumab alone or sequentially to FOLFOX relative to FOLFOX after R0 resection of colorectal liver metastasesR0 resected liver metastases from colorectal cancerEUCTR2008-004706-14-FRMicromet AG90